Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Human, Mouse, Rat, Dog
(tested or 100% immunogen sequence identity)
Western blot (1 µg/ml)
ELISA (0.05 µg/ml)
EGFR antibody was raised against synthetic peptide corresponding to aa 1170-1176 (N1170AEpYLRV1176) of EGFR (epidermal growth factor receptor) phosphorylated at Tyr1173.
Recognizes the N1170AEpYLRV motif corresponding to the major autophosphorylation site of human EGF receptor. Does not cross-react with the non-phosphorylated human, mouse, rat and dog EGF receptor or with unrelated Tyr-phosphorylated proteins. Species cross-reactivity: mouse.
Suitable for use in ELISA, Western Blot and Immunoprecipitation. Western Blot: 1 ug/ml for AP/BCIP/NBT (MTT) detection; 0.1 ug/ml for HRPO/ECL detection; Use 0.5% Casein, 0.5% BSA in PBST for blocking. Immunoprecipitation: 1-10 ug per 1E6 vanadate treated A431 cells. ELISA: 0.05 ug/ml. Positive control: H2030-03H1-Cell lysate from vanadate-treated HepG2 cells.
Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues.
Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy. Aggerholm-Pedersen N, Demuth C, Safwat A, Meldgaard P, Kassem M, Sandahl Sorensen B. Stem cells international. 2016 2016:9601493. (WB; Human)[Full Text Article]